# SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 Q2 Balance Sheet

- Company: SAREPTA THERAPEUTICS, INC. (SRPT)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001193125-26-335003
- Page: https://plicit.ai/financials/srpt/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/srpt-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 3,188,512,000 US dollars
- **Current assets**: 2,223,824,000 US dollars
- **Non-current assets**: 964,688,000 US dollars
- **Liabilities**: 1,660,714,000 US dollars
- **Current liabilities**: 502,908,000 US dollars
- **Non-current liabilities**: 1,157,806,000 US dollars
- **Equity**: 1,527,798,000 US dollars
- **Inventory**: 904,273,000 US dollars
- **Cash and cash equivalents**: 571,148,000 US dollars
- **Accounts receivable, net**: 376,824,000 US dollars
- **Short-term investments**: 217,341,000 US dollars
- **Other current assets**: 105,784,000 US dollars
- **Manufacturing-related deposits and prepaids**: 48,454,000 US dollars
- **Property and equipment, net**: 325,991,000 US dollars
- **Non-current inventory**: 226,333,000 US dollars
- **Other non-current assets**: 146,145,000 US dollars
- **Non-current investments**: 145,372,000 US dollars
- **Right of use assets**: 120,847,000 US dollars
- **Accrued expenses**: 325,232,000 US dollars
- **Deferred revenue, current portion**: 110,132,000 US dollars
- **Accounts payable**: 50,982,000 US dollars
- **Other current liabilities**: 16,562,000 US dollars
- **Long-term debt**: 847,623,000 US dollars
- **Lease liabilities, net of current portion**: 198,226,000 US dollars
- **Deferred revenue, net of current portion**: 110,132,000 US dollars
- **Other non-current liabilities**: 1,825,000 US dollars
- **Additional paid-in capital**: 6,104,530,000 US dollars
- **Common stock, $0.0001 par value, 198,000,000 shares authorized; 106,279,142 and 105,623,500 issued and outstanding, respectively, at June 30, 2026 and 105,615,096 and 104,964,220 issued and outstanding, respectively, at December 31, 2025**: 11,000 US dollars
- **Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding**: 0 US dollars
- **Accumulated deficit**: negative 4,550,915,000 US dollars
- **Treasury stock, at cost, 655,642 and 650,876 shares at March 31, 2026 and December 31, 2025, respectively**: negative 25,263,000 US dollars
- **Accumulated other comprehensive income (loss), net of tax**: negative 565,000 US dollars
- **Gross equity (calculated)**: 6,104,541,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.